NCT03898635

Retrospective Real-word Study of Linezolid for the Treatment of Tuberculous Meningitis

• Status: Unknown
• Phase: —
• Study type: Observational
• Enrollment: 150 (estimated)
• Sponsor: Huashan Hospital · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Tuberculous meningitis (TBM) is the most serious form of Mycobacterium tuberculosis infection, causing mortality and disability in more than half of the patients. Current standard treatment for TBM is based on those developed to treat pulmonary tuberculosis, which does not take into account the differential ability of anti-tuberculosis drugs to penetrate the brain. With both good central nervous system penetrance and anti-tuberculosis efficacy that have been demonstrated in drug-resistant tuberculosis, linezolid may be a promising antimicrobial in TBM treatment. The purpose of this study is to evaluate the effectiveness of linezolid in the treatment of TBM.

Conditions

• Tuberculous Meningitis

Interventions

Type	Name	Description
DRUG	Linezolid	To add linezolid 600mg or 1200mg daily in the initial or subsequent treatment regimen of TBM.

Timeline

• Start date: 2018-01-01
• Primary completion: 2019-05-01
• Completion: 2019-06-01
• First posted: 2019-04-02
• Last updated: 2019-04-02

Locations

1 site across 1 country: China